Search

Displaying results 4681 - 4690 of 7283 in total
  1. Drug

    Tisagenlecleucel

    go.drugbank.com/drugs/DB13881
    ApprovedInvestigational

    Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. … It was granted approval by FDA in August 2017 under the market name Kymriah.

  2. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] Compared to pan-PDE4 inhibitors, selective PDE4B inhibitors are associated with a lower potential for gastrointestinal adverse events.[A274581] On December 19, 2025, the U.S. … FDA approved nerandomilast tablets for the treatment of progressive pulmonary fibrosis (PPF) in adults.

  3. Drug

    Pretomanid

    go.drugbank.com/drugs/DB05154
    ApprovedInvestigational

    Persistent forms of tuberculosis (TB) have proven to be a major cause of global morbidity and mortality and a cause for significant concern. … It was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019.

  4. Drug

    Daplusiran

    go.drugbank.com/drugs/DB19331
    Investigational

    Daplusiran is under investigation in clinical trial NCT06537414 (A Study of Sequential Therapy With Daplusiran/tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis

    Synonyms: RNA, (AM-SP-(2'-DEOXY-2'-FLUORO)G-SP-AM-SP-(2'-DEOXY-2'-FLUORO)A-AM-(2'-DEOXY-2'-FLUORO)A-UM-(2'-DEOXY-2'-FLUORO)U-GM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)A-GM-(2'-DEOXY-2'-FLUORO)A-AM-(2'-DEOXY
  5. Drug

    Aspartyl-alanyl-diketopiperazine

    go.drugbank.com/drugs/DB14940
    Investigational

    Aspartyl-alanyl-diketopiperazine is under investigation in clinical trial NCT03349645 (An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee).

  6. Drug

    Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone

    go.drugbank.com/drugs/DB15235
    Investigational

    Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone is under investigation in clinical trial NCT02688101 (Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced

    Synonyms: Di-2-pyridylketone 4-cyclohexyl-4-methyl-3-thiosemicarbazone
  7. Drug

    EU204

    go.drugbank.com/drugs/DB17438
    Investigational

    EU204 (EBViNT) is an Epstein-Barr virus (EBV)-positive T-cell therapy currently undergoing phase 1 and 2a clinical trials in Korea for patients with EBV-positive lymphoma and solid cancer.

  8. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015. … Rindopepimut (CDX-110) is an injectable peptide cancer vaccine which targets a mutant protein called EGFRvIII present in about 25% to 30% of glioblastoma cases.

    Categories: Complex Mixtures
  9. Drug

    Teceleukin

    go.drugbank.com/drugs/DB15389
    Investigational

    Teceleukin is under investigation in clinical trial NCT03610490 (Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Osteosarcoma, or Pancreatic

  10. Drug

    ST-36

    go.drugbank.com/drugs/DB17275
    Experimental

    ST-36 is a cell-penetrating dominant-negative form of activating transcription factor 5. In 2017, it received orphan drug designation by the FDA for the treatment of glioma.[L47341]